A Survey on Quantitative
Claims in Direct-to-Consumer Prescription Drug Advertising
New
collection (Request for a new OMB Control Number)
No
Regular
12/21/2023
Requested
Previously Approved
36 Months From Approved
2,993
0
907
0
0
0
This survey collects insights on
consumer understanding of quantitative claims in direct-to-consumer
(DTC) prescription drug advertising. It will build on previous
qualitative research by recruiting a wider range of respondents and
weighting the data to make it nationally representative. We plan to
use an address-based mixed-mode methodology that will direct one
randomly chosen member of sampled households to complete a
20-minute online survey, with non-respondents receiving a paper
questionnaire. We will also conduct a within-survey experiment to
test whether a post-paid incentive increases survey
response.
On behalf of this Federal agency, I certify that
the collection of information encompassed by this request complies
with 5 CFR 1320.9 and the related provisions of 5 CFR
1320.8(b)(3).
The following is a summary of the topics, regarding
the proposed collection of information, that the certification
covers:
(i) Why the information is being collected;
(ii) Use of information;
(iii) Burden estimate;
(iv) Nature of response (voluntary, required for a
benefit, or mandatory);
(v) Nature and extent of confidentiality; and
(vi) Need to display currently valid OMB control
number;
If you are unable to certify compliance with any of
these provisions, identify the item by leaving the box unchecked
and explain the reason in the Supporting Statement.